Utilizing Symphony™ Aria Pharmaceuticals has developed a pipeline of promising treatments in over a dozen programs across a range of therapeutic areas. Learn more about our pipeline here: ariapharmaceuticals.com/science-and-pi…

October is #healthylungmonth! Now is the perfect time to check on your lung health and follow these tips to help prevent lung-related illnesses!

Join Aria SVP of Nonclinical R&D & Chemistry Anjali Pandey at the AFDD Summit Nov 9-11 where she'll be sharing the latest data from our #IPF program along with updates in #NASH. afdd-summit.com

It was an honor to have CEO Andrew Radin share the latest from Aria with the MIT ILP in Seoul at the Startup Showcase and meet with other industry members!

We're excited to have SVP Nonclinical R&D and Chemistry Anjali Pandey presenting our latest results in #NASH and #IPF tomorrow at the Antifibrotic Drug Development Summit.

We're please to announce the latest positive results from our IPF program presented at the AFDD Summit! This demonstrates another positive result for our lead TXR-1002 as we move closer to the clinic with a potential treatment for #IPF prnewswire.com/news-releases/…

Don't miss Aria SVP of Nonclinical R&D and Chemistry Anjali Pandey at the 6th Obesity and NASH Drug Development Summit next week where she'll be sharing the latest data from our #NASH program! obesity-and-nash-summit.com

The 6th Obesity & NASH Drug Development Summit kicks off tomorrow! Don't miss Aria SVP of Nonclinical R&D and Chemistry Anjali Pandey presenting on our latest findings in #NASH.

Thanks to Pulmonary Fibrosis News for covering our latest findings in our IPF program! Here's a nice roundup of the data Anjali Pandey presented at the Antifibrotic Drug Development Summit in Boston. pulmonaryfibrosisnews.com/news/treatment…

Promising results from the third preclinical study of TRX-1002, an #IdiopathicPulmonaryFibrosis (#IPF) treatment candidate, showed significant decrease in #AbsoluteLungWeight, #FibrosisScore, and collagen and hydroxyproline levels Aria Pharmaceuticals fal.cn/3u61e #CureIPF

Using our Symphony™ AI-platform, Aria Pharmaceuticals has developed a robust pipeline of promising treatments across a range of complex diseases. Learn more about how Symphony™ is purpose-built for biological discovery: ariapharmaceuticals.com/symphony/

"I believe it is safe to say that with these traditional lab-based approaches, we have missed potential breakthroughs." Read more from VP Discovery Aaron Daugherty on how a new approach could help us uncover new promising treatments in Drug Target Review ariapharmaceuticals.com/how-many-break…

We were pleased to have SVP of Nonclinical R&D and Chemistry Anjali Pandey present at the 6th Obesity & NASH Drug Development Summit where she presented on our latest data in #NASH. If you missed the presentation, you can now view it here: ariapharmaceuticals.com/science-and-pi…

2022 was a year of progress for Aria. CEO Andrew Radin shared his thoughts on this year's accomplishments and looks ahead at 2023 and what's to come. ariapharma.medium.com/more-progress-…

"In 2022, Aria Pharmaceuticals made significant headway on nearly every front in our mission to bring novel and needed treatments into the clinic." Read more from CEO Andrew Radin as he reflects on Aria's progress in 2022. ariapharma.medium.com/more-progress-…

"That early exploration is the phase where disruptive technology can have a significant impact and bring more potential treatments to the clinic." Read more from Aria SVP of R&D Mark G. Eller discussing technology as the new evolution in fighting diseases. pharmtech.com/view/technolog…

"The next wave of innovation in AI must examine how all the puzzle pieces of human biology are connected..." Aria SVP of R&D Mark G. Eller discussing technology as a new evolution of finding disease. ariapharmaceuticals.com/technology-as-…

Aria VP of Discovery Aaron Daugherty shares his opinion on what to expect in #AI in #drugdiscovery in 2023 in the latest edition of Drug Target Review